Background: Lamivudine and interferon have been widely used for the treatment of patients with chronic HBV infection. Serum HBV RNA is detected during lamivudine therapy as a consequence of interrupted reverse transcription and because RNA replicative intermediates are unaffected by the drug. In this study, we aimed to determine the detectability of serum HBV RNA during sequential combination therapy of interferon and lamivudine. Methods: HBV DNA and RNA in serum samples were quantified by reverse transcription of HBV nucleic acid extract and real-time PCR. Samples were analysed every 2 weeks to 3 months from three groups of patients: 10 male patients treated with nucleoside analogue monotherapy for 44-48 weeks (5 with lamivudine and 5 with entecavir), 6 males on sequential interferon and lamivudine combination therapy, and 3 males on lamivudine monotherapy for 20-24 weeks. Although effective HBV vaccines have been available for more than two decades, HBV infection remains a global health problem. It is estimated that more than 350 million people are chronic carriers of HBV worldwide [1, 2] . In the US, 1.2 million individuals have chronic HBV infection [3] . HBV infection causes a wide spectrum of clinical manifestations, ranging from acute or fulminant hepatitis to various forms of chronic liver disease, including inactive carrier state, chronic hepatitis, cirrhosis and even hepatocellular carcinoma [2, 4] .
Although effective HBV vaccines have been available for more than two decades, HBV infection remains a global health problem. It is estimated that more than 350 million people are chronic carriers of HBV worldwide [1, 2] . In the US, 1.2 million individuals have chronic HBV infection [3] . HBV infection causes a wide spectrum of clinical manifestations, ranging from acute or fulminant hepatitis to various forms of chronic liver disease, including inactive carrier state, chronic hepatitis, cirrhosis and even hepatocellular carcinoma [2, 4] .
HBV is a unique DNA virus that replicates via pre-genomic RNA. There are several key steps in HBV replication. Firstly, in the nucleus of infected hepatocytes, the asymmetric DNA in virions converts to Introduction covalently closed circular DNA (cccDNA); the cccDNA is then transcribed to pre-genomic RNA. Next, the minus strand of viral DNA is synthesized by reverse transcriptase. Finally, there is synthesis of the plus strand to form mature genomic DNA [5] . Both interferon and nucleos(t)ide analogues have been approved for the treatment of chronic hepatitis B (CHB). All of these agents have viral suppression effects, whereas interferon has additional immunomodulatory properties [6] . Lamivudine is the first approved nucleoside analogue for the treatment of CHB; however, it does not affect the integrated HBV DNAs or their transcripts, the RNA replicative intermediates [7] . Thus, lamivudine, as well as other nucleos(t)ide analogues, needs indefinite duration of therapy for continued viral suppression. By contrast, interferon has a finite duration of therapy and a higher rate of hepatitis B surface antigen (HBsAg) seroclearance than nucleos(t)ide analogues [8] . Our study and others showed that serum HBV RNA could be detected during lamivudine therapy, as the consequence of unaffected RNA replicative intermediates as well as interrupted reverse transcription [9, 10] . In addition, serum HBV RNA might serve as a predictor of early emergence of viral mutation during lamivudine therapy [10] . Previous clinical trials indicated that simultaneous combination therapy of interferon-a plus lamivudine leads to greater on-treatment viral suppression and higher sustained response rates than lamivudine monotherapy [8] . However, the detectability and patterns of serum HBV RNA in patients receiving sequential combination therapy of interferon and lamivudine compared with those on lamivudine monotherapy remain largely unknown. Thus, we explored the differential effects of interferon and lamivudine on serum HBV RNA inhibition in CHB patients with various treatment regimens.
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Methods
Patients
We enrolled 19 CHB patients treated with nucleoside analogue alone or sequential combination therapy of conventional interferon and lamivudine. These patients were divided into three groups on the basis of treatment regimen. Group I consisted of 10 male patients (mean age 44.2 years; range 30-74) treated with nucleoside analogue monotherapy for 44-48 weeks (5 patients with lamivudine and 5 with entecavir). Group II consisted of six male patients (mean age 47.3 years; range 39-56). Five of these patients were treated with lamivudine for 34-52 weeks and then shifted to conventional interferon for 24-36 weeks; there was an overlap of the two drugs for 4-20 weeks. The remaining patient in this group was treated with conventional interferon for 36 weeks and then shifted to lamivudine for 32 weeks; there was an overlap of the two drugs for 12 weeks. Group III consisted of three male patients (mean age 51.3 years; range 41-64) who were treated with lamivudine for 20-24 weeks and then followed for 22-36 weeks. Serum samples from enrolled patients were obtained just before the initiation of therapy and every 2 weeks to 3 months until the end of treatment or follow-up. These samples were stored at -80°C until use. Informed consent was obtained from each patient.
Extraction of HBV nucleic acid and reverse transcription
Extraction of HBV nucleic acid and reverse transcription with subsequent quantification were performed as previously described [10] . Nucleic acid was extracted from 100 µl serum using the SMI TEST EX-R&D kit (Genome Science Laboratories, Tokyo, Japan) and dissolved in 18 µl of ribonuclease-free water. The extract was then divided into two aliquots of equal size, termed solutions I and II. Solution I was mixed with an equivalent amount of water for DNA quantification. Solution II underwent reverse transcription using a random primer (Takara Bio Inc., Shiga, Japan) and M-MLV reverse transcriptase (ReverTra Ace, TOYOBO Co., Osaka, Japan) with subsequent DNA plus cDNA quantification. The steps in reverse transcription were as follows: 25 pM random primer was added and the sample heated to 65°C for 5 min; the sample was then put on ice for 5 min; 5× reverse transcription buffer (4 µl), 10 mM dNTPs (2 µl), 0.1 M dithiothreitol (2 µl), 8 units of ribonuclease inhibitor and 100 units of M-MLV reverse transcriptase were added; the sample was incubated at 30°C for 10 min and 42°C for 60 min; and inactivation was carried out at 99°C for 5 min.
Quantification of HBV DNA and cDNA by real-time PCR HBV DNA and cDNA quantification were performed as previously described [10] . A 1 µl aliquot of solution I and solution II were each amplified by real-time PCR with an ABI Prism 7300 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. Amplification was performed in a 25 µl reaction mixture containing SYBR Green PCR Master Mix (Applied Biosystems), 200 nM forward primer (5′-TTTGGGGCATGGACATTGAC-3′, nucleotides 1893-1912), 200 nM reverse primer (5′-GGTGAACAATGGTCCGGAGAC-3′, nucleotides 2029-2049) and 1 µl of solution I or solution II. The steps in real-time PCR were as follows: incubation at 50°C for 2 min, denaturation at 95°C for 10 min, and PCR cycling comprising 40 two-step cycles of 15 s at 95°C and 60 s at 60°C. The lower detection limit of this assay was 10 3 copies/ml. The HBV RNA quantity is obtained by subtracting the quantification result of solution I from solution II (that is, HBV nucleic acid determined by real-time PCR after reverse transcription reaction minus HBV DNA determined by real-time PCR).
Serological assays
Serum hepatitis B e antigen (HBeAg) and levels of antibodies against HBV e antigen (anti-HBe) were tested by chemiluminescent immunoassay (Architect HBeAg and Architect HBeAb, Abbott Japan, Tokyo, Japan).
Statistical analysis
Baseline characteristics including age, gender, serum alanine aminotransferase (ALT) level, HBeAg and HBV DNA level were compared among study groups. Continuous variables were expressed as mean ± sd and evaluated by Student's t-test for comparison between two groups and by Kruskal-Wallis test for comparison among three groups. Categorical variables were expressed as frequencies with proportions and compared using Pearson's χ 2 test; Fisher's exact test was applied when at least one cell of the table has an expected frequency <5. All of the tests were two-tailed and a P-value <0.05 was considered statistically significant.
Results
Demographic profiles of patients
Baseline characteristics of CHB patients treated with nucleoside analogues and/or conventional interferon are shown in Table 1 . There was no significant difference in terms of age, gender ratio, ALT level, HBeAg status or HBV DNA level among the three groups.
Serum HBV RNA levels after nucleoside analogue therapy
The detectability of serum HBV RNA before, after and at the end of nucleoside analogue therapy or follow-up is shown in Table 2 . Serum HBV RNA was undetectable in all patients before the initiation of nucleoside analogue therapy; however, it became detectable in 15 patients (79%) after therapy. Of 14 patients treated with lamivudine, serum HBV RNA was detectable in 10 (71%). By contrast, of five patients treated with entecavir, all (100%) had detectable serum HBV RNA. The peak serum HBV RNA level ranged from 4.2 to 7.0 log 10 copies/ml in lamivudine-treated patients and from 7.2 to 9.6 log 10 copies/ml in entecavir-treated patients.
Serum HBV RNA levels after interferon treatment in patients with prior lamivudine therapy
In patients with detectable serum HBV RNA after nucleoside analogue monotherapy, HBV RNA persisted until the end of therapy (group I; Table 2 ). Similarly, serum HBV RNA was persistently detectable after short-term lamivudine therapy (group III; Table 2 ). By contrast, those with sequential lamivudine and interferon therapy experienced undetectable Table 2 ).
Sequential changes of serum HBV RNA levels in patients with various treatments
The sequential changes of serum HBV RNA in patients with detectable HBV RNA in group I, II and III are shown in Figure 1 , Figure 2 and Figure 3 , respectively. As early as 2-4 weeks after starting nucleoside analogue therapy, serum HBV RNA could be detected in 13 patients (87%) and reached the peak level in 11 (73%).
Discussion
The specific presence of serum HBV RNA in patients with CHB infection was confirmed in our previous study using ribonuclease digestion [10] . Ribonuclease treatment reduced the amount of HBV DNA detected by real-time PCR after reverse transcription to about 1% of that originally detected [10] . In this study, detectable serum HBV RNA persisted during nucleoside analogue therapy including lamivudine and entecavir (group I), whereas it was inhibited under sequential lamivudine and interferon therapy (group II). The difference between these two groups is significant even in a small number of patients, demonstrating the substantial HBV RNA inhibitory effect of interferon. The decline in serum HBV RNA level was not simply the result of discontinuation of lamivudine, because serum HBV RNA was persistently detectable even after discontinuation of short-term lamivudine therapy in group III patients. The inhibition of serum HBV RNA was found in patients treated with lamivudine and then shifted to conventional interferon and in those on conventional interferon treatment and shifted to lamivudine. In the latter patients, the inhibition of serum HBV RNA might be due to the delayed therapeutic effect of interferon. Several previous studies have proven that sequential combination therapy of lamivudine and interferon has a better efficacy than lamivudine monotherapy. For example, sequential lamivudine and interferon therapy increased HBeAg seroconversion rate [11] and had a higher response rate in terms of sustained HBeAg seroconversion, ALT normalization, HBV DNA loss and reduced rates of relapse after stopping therapy [12] . In addition, the initial use of lamivudine before interferon led to an improved sustained virological response compared with the use of interferon alone from the start [13] . Nevertheless, the underlying mechanisms of these convincing findings remain unclear and deserve further investigation. In this study, the inhibitory effect of interferon on serum HBV RNA in lamivudinetreated patients might explain why these patients have a higher sustained response rate than those treated with lamivudine monotherapy. The weak point of this study is the small number of patients in groups II and III. Because this is a pilot study on the differential effects of various treatment regimens on serum HBV RNA, and because the treatment regimens in group II and group III patients are not the current standard of care, we did not intend to include additional patients treated with these regimens. In line with this study, however, our unpublished data on three patients also indicate that de novo combination therapy of pegylated interferon plus lamivudine therapy could inhibit serum HBV RNA levels. In these three patients, serum HBV RNA levels started to rise at 12-24 weeks of combination therapy and became undetectable at 48-72 weeks of therapy (YWH, JHK, et al., unpublished data). The presence of serum HBV RNA in patients treated with nucleoside analogues could be explained by in vitro data obtained in HBV-transfected HepG2.2.15 cell lines. Doong et al. [7] demonstrated that HBV-specific RNAs in cell lysate were not reduced after lamivudine and other nucleoside analogue treatments. Our unpublished data also showed persistent detectable HBV RNA in supernatant from day 4 to 17 of nucleoside analogue treatment when all the cells died (YWH, JHK, et al., unpublished data). Lamivudine and other nucleoside analogues do not affect the integrated HBV DNAs from which HBV RNAs are transcribed [7] . Further studies are needed to evaluate the effect of long-term treatment of nucleoside analogues on serum HBV RNA.
The inhibition of serum HBV RNA by interferon-a might be supported by previous studies on transgenic mice. Intrahepatic HBV replicative intermediates were cleared by a single injection of the interferon-a/b inducer polyinosinic-polycytidylic acid [14] . It was postulated that the mechanism of action of interferon involves the post-transcriptional steps of the HBV life cycle, as the intrahepatic HBV replicative intermediates were cleared while the steady-state content of HBV RNA was unaffected [14] . This same group of researchers further demonstrated that the inhibitory effect of interferona/b is at the level of the capsids containing pre-genomic RNA, acting either to accelerate their degradation or to prevent their assembly [15] . Interferon might directly inhibit HBV synthesis or could act through the cellular immune response against HBV-infected hepatocytes [16] . HBV inhibition in immortalized hepatocyte cell lines from HBV transgenic mice by interferon-b and interferon-g confirms the non-cytolytic inhibition pathway [17] . This inhibition might act through the 2′,5′-oligoadenyl synthetase/RNAse L pathway [18] . Interferon can induce this multienzyme pathway that includes 2′,5′-oligoadenyl synthetase, endoribonuclease RNAse L and 2′,5′-oligoadenyl phosphodiesterase. Among these enzymes, RNAse L theoretically inhibits all viral replication that uses an RNA intermediate step [16] . Furthermore, activation of this ribonuclease has been proposed as the major driver by which interferon inhibits viral replication [18] .
In the current study, we performed frequent detection of serum HBV DNA and RNA, in some cases as often as every 2 weeks, to determine the sequential change of serum HBV DNA and RNA during monotherapy or combination therapy. Our data showed that the peak serum HBV RNA level with entecavir treatment was significantly higher than that with lamivudine treatment (8.6 ±1.0 versus 5.6 ±1.0; P<0.001). There was also a trend towards higher detectability of serum HBV RNA in patients treated with entecavir in comparison with those treated with lamivudine (100% versus 71%; P=0.48). These findings suggest that the serum HBV RNA level might reflect the antiviral potency of nucleoside analogues [19] . Further studies are needed to clarify this interesting and important issue.
Although Rokuhara et al. [20] showed that HBV RNA was detectable before lamivudine therapy in serum samples of 24 patients, the detection rate was not specified. Their results of sucrose density gradient fractionation studies indicated that viral particles containing HBV DNA were dominant at the start of treatment, whereas those containing HBV RNA became more prevalent after 1 and 2 months of treatment. They also suggested that under untreated conditions, viral particles containing HBV RNA accounted for only about 1% of total HBV virions. However, these specific particles became the major component under lamivudine treatment [9] . They concluded, therefore, that HBV RNA particles seemed to exist in <1% of the HBV virions among patients without lamivudine treatment [21] . By contrast, the undetectable pre-treatment HBV RNA data in this study was consistent with our previous report, showing that serum HBV RNA levels increased soon after the administration of nucleoside analogues [10] . Furthermore, our data was supported by the in vitro data obtained in HBV-transfected HepG2.2.15 cell lines (YWH, JHK, et al., unpublished data), suggesting that HBV RNA was undetectable in the supernatant before nucleoside analogue treatment but became detectable after administration of these agents. In addition, Rokuhara and colleagues [20] reported a more significant decline of the serum HBV DNA level than HBV RNA level during lamivudine therapy, which confirmed our findings.
Serum HBV RNA was persistently detectable even after discontinuation of short-term lamivudine therapy in group III patients. This finding suggested that, although new viral particles containing HBV RNA were no longer produced after discontinuation of lamivudine, the existing viral particles containing HBV RNA during lamivudine administration were not quickly degraded. The study by Rokuhara et al. [20] showed a more significant decline in serum HBV DNA than RNA during lamivudine therapy, also confirming our findings on the poor immediate inhibition of serum viral particles containing HBV RNA by nucleoside analogues. Nevertheless, further studies are needed to demonstrate how long the viral particles containing HBV RNA persist in serum.
Following sequential combination therapy of lamivudine and conventional interferon, the serum HBV DNA level declined but was still detectable in all patients until the end of treatment. By contrast, serum HBV RNA was inhibited and undetectable at the end of treatment. The persistent presence of serum HBV DNA was due to the discontinuation of nucleoside analogue treatment and, thus, the lack of continuous inhibition. The shift to interferon led to the inhibition of serum HBV RNA, but the inhibitory effect of interferon on HBV DNA was not as efficient as that of the nucleoside analogue [8] . Although northern and Southern hybridization data of intracellular RNA and DNA were not available, our study and others have confirmed the possibility of detecting serum HBV RNA. We reported the discrepant measurement of HBV nucleic acid by the transcriptionmediated amplification and hybridization protection assay (TMA-HPA) and the Amplicor HBV Monitor test [10] . Because TMA-HPA uses RNA transcription and amplification of transcripts by T7 RNA polymerase [22] , we assumed that the discrepancy was a result of the persistence of serum HBV RNA in nucleoside-analogue-treated patients. Zhang et al. [9] reported the presence of serum HBV RNA in a patient treated with lamivudine. The study mainly analysed truncated HBV RNA, which was assumed to be transcribed from the integrated HBV genome; the authors showed a marked difference between truncated HBV RNA and HBV DNA. In this study, HBV DNA and HBV nucleic acid were assayed by real-time PCR and real-time reverse transcriptase PCR, and <1 log 10 difference was shown; this observation suggests that the effect of truncated serum HBV RNA was minimal. In addition, Rokuhara et al. [20] investigated the incorporation of HBV RNA into virus particles using sucrose gradient analyses: HBV RNA made a single peak in one fraction, whereas both HBV DNA and HBV core-related antigen made single peaks at three different time points during lamivudine treatment.
In conclusion, interferon can inhibit serum HBV RNA induced by lamivudine therapy. The persistence of serum HBV RNA as a consequence of unaffected HBV RNA replicative intermediates might lead to indefinite nucleoside analogue therapy. By contrast, the inhibitory effect of interferon on HBV RNA replicative intermediates might potentiate the suppression of HBV replication.
